CAP President Donald S. Karcher, MD, FCAP, discusses the FDA's new laboratory developed test regulations. "Our Number One motivation in all of our positions on LDTs is ultimately to protect patients," Karcher said. "The court does not have to make any ruling on whether or not the FDA has the authority to oversee laboratory developed tests; that's not necessary."
For the full article click here: CAP, ADLM, NILA caution court in FDA LDT decisions